Opiant Pharmaceuticals (OPNT) & Silver Bull Resources (SVBL) Critical Review

Opiant Pharmaceuticals (NASDAQ:OPNT) and Silver Bull Resources (OTCMKTS:SVBL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings and risk.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Opiant Pharmaceuticals and Silver Bull Resources, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opiant Pharmaceuticals 0 0 1 0 3.00
Silver Bull Resources 0 0 0 0 N/A

Opiant Pharmaceuticals currently has a consensus target price of $42.00, suggesting a potential upside of 185.33%. Given Opiant Pharmaceuticals’ higher probable upside, research analysts plainly believe Opiant Pharmaceuticals is more favorable than Silver Bull Resources.

Institutional and Insider Ownership

17.2% of Opiant Pharmaceuticals shares are owned by institutional investors. 37.9% of Opiant Pharmaceuticals shares are owned by insiders. Comparatively, 8.1% of Silver Bull Resources shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Opiant Pharmaceuticals and Silver Bull Resources’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Opiant Pharmaceuticals $18.45 million 3.06 $6.58 million $2.94 5.01
Silver Bull Resources N/A N/A -$3.51 million N/A N/A

Opiant Pharmaceuticals has higher revenue and earnings than Silver Bull Resources.

Risk & Volatility

Opiant Pharmaceuticals has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Silver Bull Resources has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500.

Profitability

This table compares Opiant Pharmaceuticals and Silver Bull Resources’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Opiant Pharmaceuticals -187.13% -175.03% -107.02%
Silver Bull Resources N/A -45.46% -37.56%

Summary

Opiant Pharmaceuticals beats Silver Bull Resources on 7 of the 10 factors compared between the two stocks.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.

Silver Bull Resources Company Profile

Silver Bull Resources, Inc., an exploration stage company, acquires, develops, and explores for mineral properties in Mexico and Canada. It primarily explores for silver and zinc deposits. The company holds interest in the Sierra Mojada property that includes 20 concessions covering an area of 6,496 hectares located in Coahuila, Mexico. The company was formerly known as Metalline Mining Company and changed its name to Silver Bull Resources, Inc. in April 2011. Silver Bull Resources, Inc. was founded in 1993 and is based in Vancouver, Canada.

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit